valbenazine
Sign in to saveAlso known as NBI 98854, NBI-98854
Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.
Key facts
- Drug.image
- Valbenazine.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Ingrezza
- Drug.MedlinePlus
- a617023
- Drug.DailyMedID
- Valbenazine
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N07
- Drug.ATC_suffix
- XX13
- Drug.legal_US
- Rx-only
- Drug.protein_bound
- >99%
- Drug.metabolism
- Activation by hydrolysis, deactivation by CYP3A, CYP2D6
- Drug.metabolites
- [+]-α-Dihydrotetrabenazine (active metabolite)
- Drug.elimination_half life
- 15–22 hrs
- Drug.excretion
- 60% urine, 30% faeces
- Drug.index2_label
- as salt
- Drug.CAS_number
- 1025504-45-3
- Drug.PubChem
- 24795069
- Drug.DrugBank
- DB11915
via Wikipedia infobox
~4 min read
Encyclopedic overview
13 sectionsContents
- Medical use
- Contraindications
- Adverse effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Society and culture
- Legal status
- Economics
- Names
- Research
- References
- Further reading
Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.
==Medical use== Valbenazine is used to treat tardive dyskinesia in adults. Tardive dyskinesia is a drug-induced neurological injury characterized by involuntary movements. The clinical trials that led to the approval of valbenazine by the US Food and Drug Administration (FDA) were six weeks in duration. An industry-sponsored study has studied the use of valbenazine for up to 48 weeks, in which it was found to be safe and effective for maintaining short-term (6 week) improvements in tardive dyskinesia.
Excerpted from Wikipedia’s “valbenazine” article, available under the CC BY-SA 4.0 licence.